The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How do I manage the risk of infection in patients treated with immunotherapies?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?

As Joshua Hill discusses this subject, he touches on a number of topics including the use of intravenous or subcutaneous immunoglobulins, and when to vaccinate these patients against COVID-19.


Share:

Your opinion matters

Test your knowledge! CAR-T products are more advanced than bsAbs/BiTEs in MM, and BCMA is the most popular target antigen
12 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox